http://rdf.ncbi.nlm.nih.gov/pubchem/reference/32526291

Outgoing Links

Predicate Object
contentType Journal Article|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't
endingPage 6458
issn 1078-0432
1557-3265
issueIdentifier 21
pageRange 6450-6458
publicationName Clinical cancer research : an official journal of the American Association for Cancer Research
startingPage 6450
hasFundingAgency http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b5ad88fdb9d8a30d34a9b7f844c05af4
isSupportedBy http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_365ebb6b439e217117f5f9c334529dae
http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_05f42aae6e6277a6f5ca0971f27e65e6
http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_8e5bd6e85ce2929db691e27956096b3e
bibliographicCitation Troiani T, Serkova NJ, Gustafson DL, Henthorn TK, Lockerbie O, Merz A, Long M, Morrow M, Ciardiello F, Eckhardt SG. Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model. Clin Cancer Res. 2007 Nov 01;13(21):6450–8. doi: 10.1158/1078-0432.ccr-07-1094. PMID: 17975157.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_499f7bfa23db32ceacb1c6d3f2ba382a
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_735c8b9ba8509e8f94d00d3ef0283eb2
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a705752b1370d4c45c2d1623e0591454
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f3417a3b234980eb8fac23472ccd98e5
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_31589c98a7a2dbec054a6fd5c6c609e7
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e995d11bc9f42532de0f7275af942f96
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d7e154378078c40d27bef39e7041abba
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-3369-4841
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_548895e1950de6e084a28542139aa26a
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_af320fb8d9a3ce08a1b50be813a87d14
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_020b97bec3a59bc2861c8ac01d7b4741
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-0646-4901
date 2007-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier https://pubmed.ncbi.nlm.nih.gov/17975157
https://doi.org/10.1158/1078-0432.ccr-07-1094
isPartOf https://portal.issn.org/resource/ISSN/1557-3265
https://portal.issn.org/resource/ISSN/1078-0432
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/8794
language English
source https://www.crossref.org/
https://pubmed.ncbi.nlm.nih.gov/
title Investigation of Two Dosing Schedules of Vandetanib (ZD6474), an Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Signaling, in Combination with Irinotecan in a Human Colon Cancer Xenograft Model
discusses http://id.nlm.nih.gov/mesh/M0147530
http://id.nlm.nih.gov/mesh/M0003242
http://id.nlm.nih.gov/mesh/M0016885
http://id.nlm.nih.gov/mesh/M0421253
http://id.nlm.nih.gov/mesh/M0593322
http://id.nlm.nih.gov/mesh/M0018336
http://id.nlm.nih.gov/mesh/M0185203
hasPrimarySubjectTerm http://id.nlm.nih.gov/mesh/D040262Q000037
http://id.nlm.nih.gov/mesh/D011799Q000008
http://id.nlm.nih.gov/mesh/D002166Q000031
http://id.nlm.nih.gov/mesh/D000971Q000627
http://id.nlm.nih.gov/mesh/D066246Q000037
http://id.nlm.nih.gov/mesh/D010880Q000008
hasSubjectTerm http://id.nlm.nih.gov/mesh/D000818
http://id.nlm.nih.gov/mesh/D008807
http://id.nlm.nih.gov/mesh/D006801
http://id.nlm.nih.gov/mesh/D002166Q000008
http://id.nlm.nih.gov/mesh/D003110Q000473
http://id.nlm.nih.gov/mesh/D051379
http://id.nlm.nih.gov/mesh/D000077146
http://id.nlm.nih.gov/mesh/D009368
http://id.nlm.nih.gov/mesh/D004334
http://id.nlm.nih.gov/mesh/D003110Q000188
http://id.nlm.nih.gov/mesh/D005260
http://id.nlm.nih.gov/mesh/D008279Q000379
http://id.nlm.nih.gov/mesh/D016896
http://id.nlm.nih.gov/mesh/D045744
http://id.nlm.nih.gov/mesh/D008819
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3081361
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7306
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60838
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_fddb60309b0ee16f8cd57b4b90c99e89
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_8a65ae2c3e323ad41efdc6b71be9712d
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23982

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID247533733
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129430288
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129520161
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128865459

Total number of triples: 74.